| Product NDC: | 10019-033 |
| Proprietary Name: | Fentanyl Citrate |
| Non Proprietary Name: | Fentanyl Citrate |
| Active Ingredient(s): | 50 ug/mL & nbsp; Fentanyl Citrate |
| Administration Route(s): | INTRAMUSCULAR; INTRAVENOUS |
| Dosage Form(s): | INJECTION, SOLUTION |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 10019-033 |
| Labeler Name: | Baxter Healthcare Corporation |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA019101 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20100625 |
| Package NDC: | 10019-033-72 |
| Package Description: | 10 AMPULE in 1 PACKAGE (10019-033-72) > 5 mL in 1 AMPULE (10019-033-39) |
| NDC Code | 10019-033-72 |
| Proprietary Name | Fentanyl Citrate |
| Package Description | 10 AMPULE in 1 PACKAGE (10019-033-72) > 5 mL in 1 AMPULE (10019-033-39) |
| Product NDC | 10019-033 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Fentanyl Citrate |
| Dosage Form Name | INJECTION, SOLUTION |
| Route Name | INTRAMUSCULAR; INTRAVENOUS |
| Start Marketing Date | 20100625 |
| Marketing Category Name | ANDA |
| Labeler Name | Baxter Healthcare Corporation |
| Substance Name | FENTANYL CITRATE |
| Strength Number | 50 |
| Strength Unit | ug/mL |
| Pharmaceutical Classes | Full Opioid Agonists [MoA],Opioid Agonist [EPC] |